That's precisely the key to amrns success. If only denner had the smarts to understand this, which goes to show even people with money and power aren't always the brightest. Amrn has failed not because vascepa doesn't work, bit the last 2 management teams got their panties in a bunch and didn't want to advertise for generics. What they failed to see is vascepa needs to ramp up for amrn revenues as well, regardless of how much they make. The last 2 management teams were far too focused on the money they would be generating for generics, rather than focusing on building u.s.a. and focusing on amrns revenues. This was amrns fallacy. I believe denner is headed down this road as well focusing on Europe is a big mistake and cutting expenses in u.s.a. was the biggest mistake past management's made. Denner is following in their shoes.
Ugh
News 
Market Data 
Discover 
